Cardio/Pulmonary

Higher Rehospitalization Rates in Younger SLE Patients

Save

A Medicare study shows that young adults with systemic lupus erythematosus (SLE) exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.

This study was drawn from a 20% national Medicare sample from

Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

Save

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

There has been considerable debate whether

Long-Term Benefit of Rituximab in Systemic Sclerosis

Save

A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.

Specific ACPAs and Autoantibodies Lead to RA-Associated ILD

Save

A BRASS registry study shows that specific isotypes of anti-citrullinated protein antibodies (ACPAs) can be associated with incident rheumatoid arthritis-associated ILD (RA-ILD). Early idtentification of RA-ILD is extremely important as it is a major contributor to premature death among

Poorer health outcomes for at-risk patients with fractures

Save

People at high risk of fracture who also have complex or multiple chronic medical conditions are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes, according to a new study from the Garvan Institute of Medical Research.  

These

Elevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation

Save

A Longitudinal Swedish study has shown that elevated serum uric acid (SUA) levels has cardiovascular implications and may predict the development of atrial fibrillation (AFib). 

Best of 2022: Approach to ILD in Myositis Syndromes

Save

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.

JAK Inhibitor Potential in Systemic Sclerosis-Associated ILD

Save

The occurrence of interstitial lung disease (ILD) in Systemic sclerosis portends serious morbid and mortal outcomes for those affected. This review examines the available clinical literature on the potential benefits and outcomes of JAK inhibitor use in SSc=ILD.

Overall the authors

RECITAL Trial: RTX vs. CTX in CTD-ILD

Save

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

RA-ILD takes centre stage

Save

Interstitial lung disease is common in RA, occurring in approximately 8% of RA patients. It is associated with a poor prognosis, and a median survival of 3 years. This important condition has often been neglected within the spectrum of RA research. That is changing, with excellent research

RA-ILD: an update

Save

Interstitial lung disease (ILD) remains a leading cause of mortality in rheumatoid arthritis (RA). Estimates of involvement of ILD in RA remain relatively imprecise (estimated prevalence 5-20%), though this partly reflects the wide spectrum of ILD and differing ascertainment.

ACR Best Abstracts - Day 1

Save

The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).